Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.

I, Andrieux-Meyer; SS, Tan; S, Thanprasertsuk; N, Salvadori; C, Menétrey; F, Simon; TR, Cressey; HRHM, Said; MRA, Hassan; H, Omar; HP, Tee; WK, Chan; S, Kumar; S, Thongsawat; K, Thetket; A, Avihingsanon; S, Khemnark; S, Yerly; N, Ngo-Giang-Huong; S, Siva; A, Swanson; V, Goyal; F, Bompart; B, Pécoul; S, Murad

doi:10.1016/s2468-1253(21)00031-5

Public

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.

Shared by NobleBlocks on Apr 16, 2021 • 12:00 AM UTC

Authors:

Andrieux-Meyer I

Tan SS

Thanprasertsuk S

Abstract

<h4>Background</h4>In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir has shown efficacy and safety in ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!